Karyopharm Therapeutics Inc. is a commercial-stage biopharmaceutical company specializing in the discovery, development, and commercialization of innovative cancer therapies. The company focuses on nuclear export inhibition, having developed small-molecule compounds that target exportin 1 (XPO1), a protein involved in intracellular communication between the nucleus and cytoplasm. The company's lead therapeutic product is XPOVIO (selinexor), which is approved in the United States for treating multiple hematologic malignancies, including multiple myeloma in combination with established therapies and relapsed or refractory diffuse large B-cell lymphoma as a monotherapy. Karyopharm operates primarily in the healthcare and biotechnology sectors, deriving revenue from the United States market. Headquartered in Newton, Massachusetts, the company remains dedicated to advancing novel cancer treatment options through its specialized platform targeting nuclear export mechanisms.